Metabolic syndrome associated with primary biliary cirrhosis

Journal of Clinical Gastroenterology

Volumn 49, Issue 1, 2015, Pages 57-60

  Floreani, Annarosa ^a   Cazzagon, Nora ^a   Franceschet, Irene ^a   Canesso, Fabio ^a   Salmaso, Luigi ^a   Baldo, Vincenzo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Fenofibrate; Metabolic syndrome; PBC; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; URSODEOXYCHOLIC ACID; CHOLAGOGUE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHARMACEUTICAL CARE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SURVIVAL; ANGINA, STABLE; BLOOD; COMPLICATION; ISCHEMIC ATTACK, TRANSIENT; KAPLAN MEIER METHOD; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANGINA, STABLE; CHOLAGOGUES AND CHOLERETICS; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS, BILIARY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; SURVIVAL RATE; URSODEOXYCHOLIC ACID;

EID: 84887395161     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000029     Document Type: Article

References (22)

1. Crippin JS, Lindor KD, Jorgensen R, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology. 1992;15:858-862.
2. Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265-269.
3. Allocca M, Crosignani A, Gritti A, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. 2006;55:1795-1800.
4. Floreani A, Caroli D, Variola A, et al. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int. 2011;31:361-368.
5. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
6. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715-720.
7. Alempijevic T, Sokic-Milutinovic A, Markovic AP, et al. Assessment of metabolic syndrome in patients with primary biliary cirrhosis. Wiener Klin Wochenschr. 2012;124:251-255.
8. Hindi M, Levy C, Couto C, et al. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol. 2012;47:e28-e32.
9. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008;29:777-822.
10. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol. 2001;35:531-537.
11. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, et al. The prevalence of primary non-alcoholic fatty liver disease in a population based study and its association with biochemical and anthropometric measures. Liver Int. 2006;26:856-863.
12. Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007;13:6419-6424.
13. Amarapurkar D, Kamani P, Patel N, et al. Prevalence of nonalcoholic fatty liver disease: population based study. Ann Hepatol. 2007;6:161-163.
14. Liew PL, Lee WJ, Lee YC, et al. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg. 2006;16:1584-1593.
15. Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2007;46:776-784.
16. Rajab MA, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci. 2010;5:2086-2088.
17. Poupon RE, Eschwege E, Poupon R, The UDCA-PBC Study Group. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. J Hepatol. 1990;11:16-21.
18. Combes B, Luketic VA, Peters MG, et al. Prolonged follow-up of patients in the US multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol. 2004;99:264-268.
19. Poupon RE, Lindor KD, Pares A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol. 2003;39:12-16.
20. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144:560-569.
21. Zamara E, Novo E, Marra F, et al. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol. 2004;40:60-68.
22. Floreani A, Variola A, Niro G, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol. 2008;103:1959-1965.